Skip to main content
PMC home page
The British Journal of Ophthalmology logoLink to The British Journal of Ophthalmology
. 2000 Apr;84(4):347–351. doi: 10.1136/bjo.84.4.347

Development and validation of a patient based measure of outcome in ocular melanoma

A Foss 1, D Lamping 1, S Schroter 1, J Hungerford 1
PMCID: PMC1723425  PMID: 10729289

Abstract

BACKGROUND—Patients with uveal melanoma can be treated by a number of modalities. As none of the different treatments offer a survival advantage, a key factor in choosing among treatments is their differential impact on patients' quality of life. A short, patient based questionnaire was developed and validated for evaluating outcomes following treatment for uveal melanoma.
METHODS—The 21 item measure of outcome in ocular disease (MOOD) assesses the patient's view of outcome in terms of visual function and the impact of treatment. The reliability and validity of the three MOOD scores (total, vision, impact) were evaluated in 176 patients who had been treated for uveal melanoma (75 brachytherapy, 78 proton beam radiotherapy, 23 enucleation). Of these, 165 patients also completed the SF-36.
RESULTS—All three MOOD scales met standard criteria for acceptability, reliability, and validity. The proportion of missing data was low, and responses to all items were well distributed across response categories. Internal consistency, assessed by Cronbach's alpha coefficients, exceeded the standard criterion of 0.70 for all three summary scores. Item total correlations ranged from 0.22 to 0.77 (mean item total correlation 0.58), indicating good homogeneity. Test-retest correlations for all three summary scores exceeded 0.85. Scaling assumptions, assessed by item convergent and discriminant validity correlations, were met for the vision and impact scores. The MOOD showed good content validity, as assessed by review by ophthalmologists and patients. Construct validity was demonstrated by high intercorrelations between the vision and impact scores and the total scale; higher scores for patients who reported being very satisfied compared with those who were not very satisfied and for those who reported persistent red eye compared with those who did not have this complication (known group differences/hypothesis testing); moderate correlations between the MOOD and the SF-36 and visual acuity (convergent validity); and low correlations between the MOOD and age and sex (discriminant validity).
CONCLUSIONS—The MOOD is a practical and scientifically sound patient based measure which can be used in research and audit to evaluate outcomes following treatment for uveal melanoma. It takes 5 minutes to complete and meets standard psychometric criteria for reliability and validity.



Full Text

The Full Text of this article is available as a PDF (111.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alonso J., Espallargues M., Andersen T. F., Cassard S. D., Dunn E., Bernth-Petersen P., Norregaard J. C., Black C., Steinberg E. P., Anderson G. F. International applicability of the VF-14. An index of visual function in patients with cataracts. Ophthalmology. 1997 May;104(5):799–807. doi: 10.1016/s0161-6420(97)30230-9. [DOI] [PubMed] [Google Scholar]
  2. Brenner M. H., Curbow B., Javitt J. C., Legro M. W., Sommer A. Vision change and quality of life in the elderly. Response to cataract surgery and treatment of other chronic ocular conditions. Arch Ophthalmol. 1993 May;111(5):680–685. doi: 10.1001/archopht.1993.01090050114040. [DOI] [PubMed] [Google Scholar]
  3. Char D. H., Castro J. R., Kroll S. M., Irvine A. R., Quivey J. M., Stone R. D. Five-year follow-up of helium ion therapy for uveal melanoma. Arch Ophthalmol. 1990 Feb;108(2):209–214. doi: 10.1001/archopht.1990.01070040061031. [DOI] [PubMed] [Google Scholar]
  4. Char D. H., Lonn L. I., Margolis L. W. Complications of cobalt plaque therapy of choroidal malanomas. Am J Ophthalmol. 1977 Oct;84(4):536–541. doi: 10.1016/0002-9394(77)90448-2. [DOI] [PubMed] [Google Scholar]
  5. Char D. H., Quivey J. M., Castro J. R., Kroll S., Phillips T. Helium ions versus iodine 125 brachytherapy in the management of uveal melanoma. A prospective, randomized, dynamically balanced trial. Ophthalmology. 1993 Oct;100(10):1547–1554. doi: 10.1016/s0161-6420(93)31446-6. [DOI] [PubMed] [Google Scholar]
  6. Crawford J. B., Char D. H. Histopathology of uveal melanomas treated with charged particle radiation. Ophthalmology. 1987 Jun;94(6):639–643. doi: 10.1016/s0161-6420(87)33399-8. [DOI] [PubMed] [Google Scholar]
  7. Ferry A. P., Blair C. J., Gragoudas E. S., Volk S. C. Pathologic examination of ciliary body melanoma treated with proton beam irradiation. Arch Ophthalmol. 1985 Dec;103(12):1849–1853. doi: 10.1001/archopht.1985.01050120083027. [DOI] [PubMed] [Google Scholar]
  8. Foss A. J., Whelehan I., Hungerford J. L., Anderson D. F., Errington R. D., Kacperek A., Restori M., Kongerud J., Sheen M. Predictive factors for the development of rubeosis following proton beam radiotherapy for uveal melanoma. Br J Ophthalmol. 1997 Sep;81(9):748–754. doi: 10.1136/bjo.81.9.748. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Goodman D. F., Char D. H., Crawford J. B., Stone R. D., Castro J. R. Uveal melanoma necrosis after helium ion therapy. Am J Ophthalmol. 1986 Jun 15;101(6):643–645. doi: 10.1016/0002-9394(86)90762-2. [DOI] [PubMed] [Google Scholar]
  10. Gragoudas E. S., Egan K. M., Seddon J. M., Walsh S. M., Munzenrider J. E. Intraocular recurrence of uveal melanoma after proton beam irradiation. Ophthalmology. 1992 May;99(5):760–766. doi: 10.1016/s0161-6420(92)31900-1. [DOI] [PubMed] [Google Scholar]
  11. Guyer D. R., Mukai S., Egan K. M., Seddon J. M., Walsh S. M., Gragoudas E. S. Radiation maculopathy after proton beam irradiation for choroidal melanoma. Ophthalmology. 1992 Aug;99(8):1278–1285. doi: 10.1016/s0161-6420(92)31832-9. [DOI] [PubMed] [Google Scholar]
  12. Kim M. K., Char D. H., Castro J. L., Saunders W. M., Chen G. T., Stone R. D. Neovascular glaucoma after helium ion irradiation for uveal melanoma. Ophthalmology. 1986 Feb;93(2):189–193. doi: 10.1016/s0161-6420(86)33770-9. [DOI] [PubMed] [Google Scholar]
  13. Lee P. P., Spritzer K., Hays R. D. The impact of blurred vision on functioning and well-being. Ophthalmology. 1997 Mar;104(3):390–396. doi: 10.1016/s0161-6420(97)30303-0. [DOI] [PubMed] [Google Scholar]
  14. Macfaul P. A., Bedford M. A. Ocular complications after therapeutic irradiation. Br J Ophthalmol. 1970 Apr;54(4):237–247. doi: 10.1136/bjo.54.4.237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. McHorney C. A., Ware J. E., Jr, Lu J. F., Sherbourne C. D. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994 Jan;32(1):40–66. doi: 10.1097/00005650-199401000-00004. [DOI] [PubMed] [Google Scholar]
  16. Meecham W. J., Char D. H., Kroll S., Castro J. R., Blakely E. A. Anterior segment complications after helium ion radiation therapy for uveal melanoma. Radiation cataract. Arch Ophthalmol. 1994 Feb;112(2):197–203. doi: 10.1001/archopht.1994.01090140073026. [DOI] [PubMed] [Google Scholar]
  17. Seddon J. M., Gragoudas E. S., Albert D. M., Hsieh C. C., Polivogianis L., Friedenberg G. R. Comparison of survival rates for patients with uveal melanoma after treatment with proton beam irradiation or enucleation. Am J Ophthalmol. 1985 Mar 15;99(3):282–290. doi: 10.1016/0002-9394(85)90357-5. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Publishing Group

RESOURCES